AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results
Conference Call and Webcast on November 6, 2012
REDWOOD CITY, Calif.,
Nov. 1, 2012 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release
third quarter 2012 financial results after market close on
Tuesday, November 6, 2012. AcelRx
management will host an investment-community conference call at
4:30 p.m. Eastern time (1:30 p.m. Pacific time) on November 6, 2012 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (800) 860-2442 for domestic callers, (866) 605-3852
for Canadian callers or (412) 858-4600 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investor Relations section of
the company's website at www.acelrx.com.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor Relations section
of the company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of acute and breakthrough pain. AcelRx's lead
product candidate, the ARX-01 Sufentanil NanoTab PCA System, which
is currently in Phase 3 clinical development, is designed to solve
the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the inherent potential for
programming and delivery errors associated with the complexity of
infusion pumps. AcelRx has two additional product candidates which
have completed Phase 2 clinical development: ARX-02 for the
treatment of cancer breakthrough pain, and ARX-03 for mild
sedation, anxiety reduction and pain relief for patients undergoing
painful procedures in a physician's office. AcelRx plans to
initiate a Phase 2 study for a fourth product candidate, ARX-04, a
sufentanil formulation for the treatment of moderate-to-severe
acute pain, funded through a grant from USAMRMC. For
additional information about AcelRx's clinical programs please
visit www.acelrx.com.
Forward Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates, and the
therapeutic potential of AcelRx Pharmaceuticals' product
candidates. These forward-looking statements are based on
AcelRx Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals'
actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without
limitation, risks related to: the success, cost and timing of
AcelRx Pharmaceuticals' product development activities and clinical
trials; the success of its patent prosecution strategy; its ability
to protect its proprietary technology, including the risks that
pending patent applications may not result in issued patents; its
ability to obtain sufficient financing to complete development and
registration of its product candidates in the United States and Europe; its ability to obtain and maintain
regulatory approvals of its product candidates; the market
potential for its product candidates; and other risks detailed in
the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S.
Securities and Exchange Commission filings, including its Quarterly
Report on Form 10-Q for the three months ended June 30, 2012. AcelRx Pharmaceuticals undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.